The formal rulemaking process that follows is the real regulatory decision, and consumers should follow that process rather than assuming yesterday's vote has already cleared these substances for safe use
BPC-157 alone makes sense when: you have an isolated injury (specific tendon, recovering surgical site, gut-lining concerns from NSAID use), or you want to evaluate how BPC-157 affects you before adding another peptide
Retatrutide is an investigational triple receptor agonist (GLP-1, GIP, glucagon) that remains unlicensed in the UK, with no MHRA approval, no NHS availability, and no BNF listing as of 20242025
The anatomy itself creates challenges
Marketing and Advertising Risk Don't say or imply BPC-157 heals injuries, repairs tissue, treats the gut, or cures pain